The Charter of the Prix Galien Digital Health Committee


The Prix Galien rewards excellence and novelty and awards additional honors to those who show great promise in the fields of innovative digital healthcare applications or devices and serve humanity at large. The products considered for the Prix Galien Digital Health Award must 3 criteria among the followings:
• Clinical validations (min 2 papers) or FDA Approved
• Average annualized return of at least 20% in the past 3 years
• Turnover > $ 1 M in the past 12 months or 20% average annual growth over the past three years
• International References
• At least 10 or more employees at launch
• Have demonstrated satisfactory usage outcome (>80%)

The committee will award one prize. As to the science, candidates will be chosen from among all therapeutic or medical categories-- and each will be judged against all others.
The prize will be awarded for a digital application in medical science that improves the human condition, principally based on two criteria:
One: What was innovative in the course of this product’s scientific development, application or clinical utility?
Two: How did the digital technology make this medical application possible & meaningful?

Criteria that will not be considered are the size of the market, the cost of development or the contingencies of distribution. The Committee has the right to not select a winner in a particular year.

Other new awards, consistent with the mission of the Galien Foundation, are planned. At the discretion of the committee, these awards will be judged by the committee members.

The awards committee will be composed of up to eight individuals and an honorary member chosen by the Board of the Galien Foundation. Except at the onset, committee members will generally serve for one, or a maximum of two, five-year terms. Membership terms will be staggered to ensure optimal transition. Members will be highly distinguished individuals from the scientific research and business communities, primarily from the US, but with at least one international member. In addition to outstanding academic credentials, committee members must have demonstrated expertise and understanding of human therapeutics and must be familiar with global healthcare issues. The Board, in consultation with the committee, will choose a Chair, who will serve for one, or a maximum of two seven-year terms

The Board will entertain nominations for the committee from current committee members, former committee members, the academic and research communities, and from the scientific divisions of companies engaged in the development of human therapeutics.

The decisions of the independent committee with respect to the selection of winners for awards will be final and wholly the decision of the committee. The committee deliberations will be conducted in private, and without any input whatsoever from the Board of the Foundation, or from Member organizations or other sponsors.